Thesis (M.H.S.A.)--University of Michigan, 1981.

Thesis (M.H.A.)--University of Michigan, 1974. / eContent provider-neutral record in process. Description based on print version record.

Reimbursement of costs in trial proceedings and enforcement proceedings Abstract Thesis reimbursement of costs in trial proceedings and enforcement proceedings describes and evaluates selected concepts concerning the reimbursement of costs in trial proceedings and enforcement proceedings. The primary goal is to describe essence of reimbursement of costs and to answer this common question: "Who shall pay it in the end?". Thesis is dived into four parts. The thesis starts with introduction where author sets goals of the thesis and methods of scientific work to compile and process assigned subject. In the first part author briefly defines terms trial proceedings and enforcement proceedings in order to clarify subject of the thesis. Furthermore there is briefly defined distinction between reimbursement of costs and payment of costs. The second part of the thesis is concerned with reimbursement of costs in trial and adversarial proceedings. This part is the most extenstive and most evaluated. It consists of description of reimbursement of costs and types of costs. There is also dedicated part to decisions and remedies concerning the reimbursement of costs. Third part is concerned with reimbursement of costs in trial and non-adversarial proceedings. Third part is divided into three chapters according to the...

O presente estudo procurou obter uma estimativa dos custos diretamente ligados ao atendimento de lesões traumáticas maxilofaciais em crianças e adolescentes, comparados com a população adulta acometida do mesmo agravo, bem como o perfil sóciodemográfico da população atendida em um Hospital Público do Município de São Paulo, Brasil,com o intuito de fornecer evidências para avaliação quantitaiva do dano em perícias odontolegais,. Material e Método. Os dados dos prontuários foram colhidos, no período de janeiro de 2002 a dezembro de 2008 dos pacientes atendidos no serviço de Cirurgia Buco-Maxilofacial de um hospital do município de São Paulo. As variáveis classificatórias foram descritivamente apresentadas em tabelas de contingência contendo frequências absolutas (n) e relativas (%). A associação entre elas foi avaliada com o teste Qui-quadrado ou teste da razão de verossimilhança. Para a análise dos custos diretos foram utilizados os valores de referência da Tabela do Sistema de Informações de Tratamento Ambulatorial do Sistema Único de Saúde- SIA-SUS do Ministério da Saúde. Resultados Do1.200 casos analisados, 419preencheram os requisitos da pesquisa. O grupo caso obteve 108 registros (faixa etária até 19 anos), e os demais foram classificados, como grupo controle (acima de 20 anos de idade). O grupo caso apresentou uma incidência de 1,5% ao ano de lesões traumáticas, e a média de idade no grupo caso foi de 14,35 +- 4,76 e no grupo controle foi de 33,65 +- 11,73 anos de idade. Em relação ao sexo predominaram os indivíduos do sexo masculino em ambos os subgrupos O tipo de tratamento cirúrgico prevaleceu em ambos os subgrupos, e o tempo de internação em dias foi cerca de duas vezes maior no grupo controle em relação ao grupo caso, entretanto as complicações foram mais freqüentes no grupo caso em relação ao grupo controle. Os tipos de lesões mais freqüentes no grupo caso foram as fraturas nasais/dentárias, seguidas das fraturas e mandíbula, e que no grupo controle o quadro inverteu-se. A distribuição de custos teve o maior número de casos na faixa de custos até R$500,00 em ambos os subgrupos amostrais A freqüência de ocorrência de complicações foi significativamente maior no grupo caso, em relação ao grupo controle, da mesma forma que os retornos ambulatoriais foram também significativamente maiores neste grupo. Conclusões A distribuição de custos teve o maior número de casos na faixa de custos até R$500,00 em ambos os subgrupos amostrais; esses custos foram calculados com base no repasse de verbas da Tabela de Valores do Sistema Único de Saúde, onde não esta discriminado o custo dos honorários profissionais. A valoração do dano nas atividades periciais deve considerar, além dos custos diretamente envolvidos com o atendimento do traumatizado, as consequências para suas atividades diárias especialmente quando se trata de criança ou adolescentes cuja função social ainda está por se definir / The aim of this study is to provide evidence for the quantitative assessment of injury in forensic dentistry investigation, thorough the estimate of costs directly linked to the care of maxillofacial trauma lesions in children and adolescents, compared to adults who suffered the same injuries, as well as trace a social demographic profile of the patients admitted in a public hospital in Sao Paulo. Material and Method. The hospital chart data were collected from January 2002 to December 2008 and the charts belonged to patients cared for by the Buco-Maxillofacial Surgery Department of a hospital in Sao Paulo. Classification variables were described in contingency tables which comprise absolute (n) and relative (%) frequencies. Their association was assessed using the chi-square test. Reference prices from the Ambulatory Care Price Table, provided by the Unified Health System (SIA-SUS), the government managed Public Health System in Brazil, were used to determine direct costs. Outcome: out of the 1200 cases analyzed, 419 matched the requisites of this survey. The case group comprised 108 cases (up to 19 years old) and the other 311 were classified as the control group (above 20 years old). The incidence rate of trauma lesions was of 1,5% per year in the case group and the average age was of 14,35 +-4,76, while in the control group, the average age was 33,65 +- 11,73. Male individuals prevailed in both groups and so did the surgical treatment. The number of days of hospital stay was about twice as big in the control group in relation to the case group. Complications, however, were more frequent in the case group. The most frequent kinds of lesion in the case group were the dental or nasal fractures, followed by jaw fractures, and this was directly opposite to what happened in the control group. The Unified Health System (SUS) reimbursed treatments of up to 500 reais in both groups. The frequency of complications and returns to the Ambulatory Care facilities were significantly higher in the case group. Conclusion: The reimbursement of expenses happened more frequently when treatment cost up to 500 reais in both sample groups. These costs were calculated taking reference prices from the Ambulatory Care Price Table, provided by Unified Health System (SUS). The prices dont include professional fees. When calculating how much to refund, the Government should take into account not only the direct costs involved in caring for the injured patient, but also the consequences such treatments have on their daily activities, especially when we consider that children and adolescents do not have a their social roles defined yet.

八零年代起，我國政府即對生技新藥產業寄予厚望，為促使生技醫藥產業成為明星產業，行政院也自1982年起，將生物技術列為國內八大重點科技產業之一，並投入相當大的金額補助產業之發展；至今已歷經35年，卻仍僅極少由台灣本土研發之新藥成功上市。 本研究主要採用文獻探討以及個案訪談作為主要的研究方法，先藉由文獻探討建立起論文整體之架構，之後再透過兩間國內本土新藥研發公司的訪談加以實證。本研究探討衛生福利部中央健康保險署現行之藥價政策對於國內本土研發新藥上市策略之影響，以及《全民健康保險藥物給付項目及支付標準》第17-1條實施後，是否有助於國內本土研發新藥上市的問題，進行深入分析與探討。而可得到以下初步之研究結論： 一、我國政府的鼓勵措施對於台灣的新藥發展之影響 我國政府多以科技專案補助臨床試驗的形式協助國產新藥公司研發新藥。 二、比較在台灣及其他國家研發新藥的鼓勵措施 我國與日本政府皆有提供新藥不同形式之新藥相關加成給付；本研究未發現韓國政府有針對新藥提供相關加成給付措施。 三、台灣健保藥價制度與台灣研發的新藥藥價 1.對新藥開發類型之國產新藥公司而言，期望政府在設定參考藥品之藥價時，可以選擇使用參考藥品之初始藥價作為reference price。 2.對新藥開發類型之國產新藥公司而言，期望在選擇參考藥品時，可以鼓勵創新藥理作用之新藥、跳脫侷限治療相同疾病用藥之思維。 3. 對新藥開發類型之國產新藥公司而言，全民健康保險藥物給付項目及支付標準第17-1條規範參考類似藥品之十國藥價不合理，因為若以台灣為第一上市國，則尚未在其他國家取得藥價，此法規自相矛盾。 四、我國藥品政策與台灣研發新藥上市策略 對新藥開發類型之國產新藥公司而言，健保給付國產新藥之藥價無法符合國產新藥公司期望之藥價，國產新藥公司改採取由病患自費購買藥品的方式銷售。 / Since the 1980s, our government has placed great hopes toward the industry of biotech and new drugs in order to take such industry to a booming stage. The Executive Yuan has also listed biotechnology as one of the eight key technological industries in the country since 1982. Furthermore, large amounts of subsidies have aided the development of this industry. This industry has been in development for 35 years, however, very few new drugs developed by domestic pharmaceutical companies have been launched successfully in Taiwan. This study mainly used literature review and case interview as the main research methods. Firstly, the structural development of the thesis was built on reviewing past literature. Then, the empirical study was conducted through interviews with two domestic new drug research and development pharmaceutical companies. This study examined the impact of the current drug pricing policy of the National Health Insurance Administration on the domestic market for research and development of new drugs. Moreover, the effectiveness of implementation of Article 17-1 of the "National Health Insurance Drug Payment Program and Payment Standards" was investigated in relations to the development of domestic new drugs in the country. In-depth analysis was employed to explore and discuss our research. The following preliminary conclusions were obtained: First, the influence of the government's encouragement measures on the development of Taiwan's new drugs was examined. Results revealed that the government have mainly been funding domestic new drug companies to research and develop new drugs through subsidized clinical trials of technological projects. Second, the encouragement measures for developing new drugs in Taiwan and other countries were compared. Results showed that both Taiwan and the Japanese government have been providing new forms of new-drug-related premiums for new drugs. However, in this study, we did not find the Korean government providing relevant premiums measures for new drugs. Third, we explored the drug price system of Taiwan's national health insurance and the prices of new drugs that were developed domestically. We found that 1) for domestic pharmaceutical companies that specializes in developing new drugs, they anticipate the government to use the initial drug prices of the reference drugs as reference prices when setting the prices of reference drugs; 2) for domestic pharmaceutical companies that specializes in developing new drugs, they anticipate the government to encourage innovations of new drugs leading to new pharmacological effects and overcoming the idea of limiting treatment to the same illness or conditions when they are selecting reference drugs; 3) for domestic pharmaceutical companies that specializes in developing new drugs, under Article 17-1 of the "National Health Insurance Drug Payment Program and Payment Standards", the statement that drug prices should be referenced from ten countries is unresonalbe because prices cannot be obtained from other countries if Taiwan is the first country to launch the new drug. Thus, the regulation is contradictory in itself. Fourth, we examined Taiwan’s pharmaceutical policy and the marketing strategy of new drugs developed domestically. Findings showed that for domestic drug companies that specializes in developing new drugs, when the drug payment provided by the national health insurance does not meet the drug prices set by the new drug companies, these companies employ a strategy that the patient pay for the drugs instead of the national insurance system.

Reimbursement of the legal representation in civil proceedings with special focus on petty legal disputes This thesis concerns with a development and current legislation and case law of the higher courts in cases of granting compensation for legal representation in court proceedings. After a brief historical excursion is described current legislation of the negotiation and providing a fee for legal services of attorney. Given the fact that's attorney's remuneration is granted as a part of the costs of proceedings, this thesis describes general rules for granting mentioned costs with a special focus on reimbursement of representation, in particular is discussed in terms of the effectiveness of legal representation. In the following, the largest part of the thesis issues recent development of costs of proceedings in "petty disputes" including a judicature of Supreme Court and Constitutional Court in a variety of situations. Described section of thesis briefly but comprehensively presents attitudes and intellectual trends of courts and legislators in concerned area. The thesis subjected the current legislation and case law to a criticism, and found out that in some cases is judicature and legislation in contrast of basic law principles and equity principle. The other two sections of thesis are mainly...

This diploma thesis Reimbursement of costs in trial proceedings and enforcement proceedings describes the main aspects related to reimbursement of costs in the two kinds of civil procedure. Reimbursement of costs is seen as a secondary topic, but can cause serious property issues to the parties. The purpose of this thesis is to provide a comprehensive look at the issue of reimbursement of costs in trial and enforcement proceedings. The thesis is composed of an introduction, two main sections which are dealing with reimbursement of costs in trial proceedings and reimbursement of costs in the enforcement proceedings and conclusion. In the introduction I'm dealing with the reasons why I've chosen this topic. The actual text of the thesis is divided into two main parts - reimbursement of costs in trial proceedings and reimbursement of costs in the enforcement proceedings. The first part deals with selected kinds of costs, with an emphasis on case law, and also deals with the issues connected with the abolition of regulation No. 484/2000 Coll. Within subchapters 1.2 and 1.3 I analyze reimbursement of costs in the contentious and non-contentious proceedings, individual principles governing the reimbursement of costs and institutes related to reimbursement, specifically pre- action appeal and the...

1 Summary This thesis investigates the main perspectives of the reimbursement of costs in trial proceedings and enforcement proceedings. During the process of the judicial decision- making is often the issue of reimbursement of costs in trial proceedings and enforcement proceedings considered as of lesser importance. Nevertheless, the extent of professional discussion and frequent amendments of relevant legal regulations testify the very opposite. For this reason, one of the basic aims of this study was to perform a solid analysis of relevant legal adjustments, to point out the real problems while applying them and also to bring the suggestions of possible changes of particular legal regulations. The parts of this thesis are as following - introduction, five chapters, and conclusion. In the introductory part, the author defines the issue and aims of the work which are further described in following chapters. It also contains a definition of basic and key terminology. The first chapter introduces an overview of types of particular costs in trial proceedings, which are essential for understanding the principles and their consequent reimbursements. Alongside with a summary of historical evolution, the author also included practical enforcement and last but not least - the most frequent difficulties of...

The objective of my thesis is to summarize activities realted to pricing of drugs, describe ways of launching drugs in the Czech market, present the pricing policy in various stages, forms of price regulation and ways of setting prices and reimbursement. The thesis provides information about steps and issues in the pricing policy by reviewing the existing situation.

This diploma thesis deals with the topic of reimbursement of costs in trial proceedings and enforcement proceedings. The main goal of this thesis is to provide a comprehensive overview of the topic and to explain fundamental aspects of costs in trial proceedings and enforcement proceedings as well. The diploma thesis focuses not only on the interpretation of legal provisions but also on the case law, which is cited throughout the text. The diploma thesis consists of an introduction, two main chapters, and a conclusion. The first chapter discusses reimbursement of costs in trial proceedings and is systematically segmented according to corresponding phases of a trial proceeding. The first part of this chapter describes costs in trial proceedings. The following subchapters discuss principles of cost reimbursement in contentious proceedings. The subchapter 1.3.3 focuses on legal conditions for awarding costs with an emphasis on the discretionary power of the courts and pretrial notice. The subchapter 1.4 deals with reimbursement of costs in non-contentious proceedings. The last part of this chapter discusses remedies directed against decisions regarding costs in trial proceedings, including the constitutional complaint. Reimbursement of costs in enforcement proceedings under the Enforcement Regulations...